REVIEW OF CLINICAL TRIALS WITH SODIUM GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS

Аннотация

This review article summarizes and analyzes clinical trials assessing the efficacy and safety of SGLT2 inhibitors, a class of drugs used primarily for the treatment of Type 2 diabetes mellitus. The review covers several key studies, including the EMMY, EMPAREG OUTCOME, DAPA-HF, EMPULSE, SOLOIST-WHF and EMPACT-MI trials, highlighting the positive impact of SGLT2 inhibitors on reducing cardiovascular events and improving kidney outcomes. The article further discusses the expansion of SGLT2 inhibitors' use beyond diabetes treatment to address heart failure and chronic kidney disease. The authors conclude that SGLT2 inhibitors offer significant benefits in managing type 2 diabetes mellitus and related complications, while also demonstrating promise in broader therapeutic areas. This review is essential for understanding the evolving role of SGLT2 inhibitors in modern clinical practice and provides valuable insights into ongoing research. It is particularly relevant to my study on the cardiovascular benefits of medications and their long-term effects.